When will Eli Lilly's weight loss pill be available? Orforglipron is not on shelves yet — here's the FDA timeline, expected cost, and what we know.
Eli Lilly's weight loss pill is not available by prescription yet. The drug is orforglipron, a once-daily oral GLP-1 pill that Lilly has studied in late-stage trials and has said it planned to submit to the FDA for chronic weight management. If the FDA approves it, a US launch in 2026 is the most realistic window, but no date is confirmed and no pharmacy can fill a prescription today.
What Is Eli Lilly's Weight Loss Pill?
Orforglipron is an investigational, once-daily tablet. Unlike oral semaglutide products such as Rybelsus, it does not have to be taken on an empty stomach with a limited amount of water, which makes it simpler to use.
- Drug class: GLP-1 receptor agonist, but built as a small molecule rather than a peptide.
- How it is taken: One tablet daily, with or without food.
- What it is studied for: Chronic weight management and type 2 diabetes.
- Status: Investigational. Orforglipron is not FDA-approved for any use in the United States.
Because it is a pill, news coverage often calls it "the Eli Lilly weight loss pill." If you have seen the name Foundayo attached to Lilly's oral weight loss pill, the availability answer does not change: it is not on the market yet.
What the Phase 3 Trial Data Showed
Lilly reported results from the ATTAIN-1 trial in 2025. Participants taking the highest dose of orforglipron lost an average of about 12.4% of their body weight over 72 weeks, compared with roughly 0.9% for those taking a placebo. That works out to about 27 pounds for a person who started around 220 pounds.
In the ACHIEVE program, which enrolled people with type 2 diabetes, orforglipron outperformed oral semaglutide on blood sugar and weight in a head-to-head study.
Two cautions are worth remembering about these numbers:
- Trial averages are not promises — some participants lost far more weight, and some lost very little.
- Everyone in the studies also received diet and exercise counseling, which is standard in modern weight-management trials.
When Will the Eli Lilly Weight Loss Pill Be Available?
Lilly has signaled that it planned to file for FDA approval, and company statements have pointed to a possible commercial launch as early as 2026. The FDA's standard review clock runs about 10 to 12 months from the date a complete application is accepted, while a priority review would shorten that to roughly six months.
Several factors can move that date:
- Review delays, additional data requests, or an FDA advisory committee meeting.
- Manufacturing scale-up, which slowed earlier GLP-1 launches.
- Label negotiations, including which patients the drug is ultimately approved for.
Approval and availability are two different milestones. A medicine can be approved and still take weeks or months to reach pharmacies, and insurance coverage often lags behind the launch.
What Will the Eli Lilly Weight Loss Pill Cost?
When people search for the Eli Lilly weight loss pill cost, the honest answer today is that no price has been published. Lilly has not announced a list price or a cash-pay price for orforglipron.
For context, cash prices for existing injectable options have fallen sharply. Single-dose tirzepatide vials sold through LillyDirect have started around $349 to $499 per month for self-pay patients, and NovoCare offers Wegovy at roughly $499 per month for cash customers. List prices for both remain above $1,000 per month before discounts and rebates.
Analysts generally expect an oral GLP-1 to be priced competitively because tablets are cheaper to manufacture than injections. Coverage is a separate question, since many commercial plans require prior authorization or step therapy for weight-loss drugs, and Medicare Part D does not cover medicines used only for weight loss.
| Option | Form | Status | Typical cash price per month |
|---|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | FDA-approved for obesity | About $349–$499 via LillyDirect; $1,000+ list |
| Semaglutide (Wegovy) | Weekly injection | FDA-approved for obesity | About $499 via NovoCare; $1,300+ list |
| Oral semaglutide (Rybelsus) | Daily tablet | Approved for type 2 diabetes | Varies; often $900+ list |
| Orforglipron (Lilly pill) | Daily tablet | Investigational | Not announced |
How It Compares With Today's Weight Loss Drugs
Injectables still produce the largest average weight loss in trials. Tirzepatide has shown roughly 20% or more weight reduction in the SURMOUNT program, and semaglutide about 15% in STEP-1, both higher than orforglipron's 12.4% in ATTAIN-1. Those are cross-trial comparisons, so they are imperfect because the studies enrolled different populations.
If you are choosing among injectables right now, the question of tirzepatide vs semaglutide which is better for weight loss usually comes down to average weight loss, tolerability, and cost.
Pills have real advantages of their own: no needles, easier storage, and no cold chain. Coverage rules for semaglutide oral for weight loss are still evolving, and dosing is a common concern — the starting dose of semaglutide for weight loss is intentionally low to reduce nausea, which is why it takes weeks to reach a full therapeutic dose.
Side Effects, Safety, and Other Options People Ask About
GLP-1 medicines share a similar side effect profile. Nausea, vomiting, diarrhea, and constipation are the most common complaints, and they often ease after a few weeks. The drug class also carries a boxed warning about thyroid C-cell tumors seen in rodents, although that risk has not been established in humans.
These medicines are not recommended during pregnancy, and people with a personal or family history of medullary thyroid cancer or MEN2 should not take them. Talk with a healthcare professional before starting, stopping, or switching any weight-management medication, including products sold without a prescription.
People looking for cheaper, non-prescription options often ask does l carnitine help with weight loss or does kpv help with weight loss. The evidence for both is far weaker than for prescription GLP-1 drugs, and most supportive claims come from small studies or personal anecdotes rather than large randomized trials.
Frequently Asked Questions
Is Eli Lilly's weight loss pill available right now?
No. Orforglipron is still investigational in the United States and is not FDA-approved for weight loss, so it cannot be prescribed or sold at a pharmacy. Lilly has indicated it planned to file for approval, and if the FDA grants it, a launch in 2026 is possible. Any website claiming to sell "Lilly's weight loss pill" today is not selling an approved product.
How much will the Eli Lilly weight loss pill cost?
Lilly has not announced a price for orforglipron. For reference, self-pay prices for current GLP-1 drugs run about $349 to $499 per month through manufacturer-connected pharmacies, while list prices are above $1,000. Analysts expect an oral option to be priced competitively, but insurance coverage will vary widely by plan.
Is Foundayo the same as Eli Lilly's weight loss pill?
Foundayo is a name that has appeared in online searches and coverage tied to Lilly's oral GLP-1 weight loss pill, which is orforglipron in clinical trials. No version of that pill is FDA-approved or for sale in the United States yet, so "is Foundayo available now" has the same answer as the orforglipron timeline: not yet.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.